Conclusions Equality of access to specialist treatments for IPF remains a challenge. There is wide variation in the number of referrals to our specialist centre per patient population. The reasons for this disparity could be lack of detection of IPF, physician or patient factors. This presents a continued challenge for IPF management. 
Background Idiopathic pulmonary fibrosis (IPF) is a rare disease, and estimates of incidence and prevalence vary considerably by geographic region. There have been few studies of patient populations with IPF in Sweden and here we describe the first national cohort of patients with pulmonary fibrosis. Methods A retrospective longitudinal study with linked datasets from Swedish population-based registers and electronic medical records from 2001-2017. Included patients had a registration of International Classification of Diseases, Tenth Revision (ICD-10) code J84.1, were aged 40 years and did not have a competing diagnosis after the initial J84.1 code; a diagnosis algorithm was used to refine the population for patients with IPF. This national cohort was based on linked patient-level data from national, population-based health registers. Objectives To describe incidence of pulmonary fibrosis and clinical characteristics (comorbidities and concomitant medications) at diagnosis and at any time.
Results Cohort 1 included 17 244 patients with pulmonary fibrosis. Incidence of pulmonary fibrosis ranged from 10.4-15.4 cases per 1 00 000 per year between 2001 and 2015, with an incidence of 13.9 cases per 1 00 000 per year in 2015. Incidence increased with age and was higher in males. Patients had a mean (standard deviation [SD] ) age of 74.6 (10.5) years at time of diagnosis and 62.5% were male. Clinical characteristics of these patients are shown in the table; patients had a mean (SD) Charlson comorbidity index of 1.4 (1.7). Conclusions Analysis of the first national cohort of patients with pulmonary fibrosis in Sweden has found slightly higher incidence rates of IPF than those of previous studies, though this may be due to identification of patients with IPF using ICD-10 code J84.1 ('other interstitial pulmonary diseases with fibrosis'). Though a diagnosis algorithm was used to refine the population for those with IPF, these criteria might not exclude all patients with non-IPF interstitial lung diseases. The frequencies of clinical characteristics in this population were broadly in line with those previously observed in patient populations with IPF.
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NECK AS MEDIASTINAL EXTENSION: DIAGNOSIS OF SARCOIDOSIS BY CORE BIOPSY OF CERVICAL LYMPH NODES
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Background Sarcoidosis is a multi-system granulomatous disease of uncertain aetiology. It is characterised by bilateral hilar lymphadenopathy. The diagnosis is best supported by the histological evidence of non-caseating granulomas in the affected organ (s). The diagnostic procedures for histological confirmation are invasive and a less invasive approach to diagnostic pathway is warranted. Objectives The utility of diagnostic value of neck ultrasound was retrospectively evaluated in this study. A histological diagnosis was made by ultrasound guided head and neck core biopsy to confirm clinically and radiologically suspected sarcoidosis.
Methods Following clinical assessment by a respiratory physician, 25 patients were referred for sonographic evaluation of the head and neck by a thoracic radiologist after CT scan in an attempt to avoid the use of more invasive and expensive tests such as endobronchial ultrasound (EBUS) and mediastinoscopy. Typically these patients had obvious mediastinal adenopathy +/-parenchymal lung disease, but not clinically apparent neck nodes. Where no cervical lymph node suitable for biopsy was seen, the parotid glands were evaluated and biopsied if deemed abnormal. Patients with no suitable lymph nodes and normal parotid glands were returned for consideration of other diagnostic techniques.
Results A diagnosis of sarcoidosis was made in all cases where a core biopsy of cervical lymph nodes (figure 1) was attempted (23 out of 25 patients). It is emphasised that the cervical lymph nodes in this series were not particularly enlarged, short axis dimensions being under 10 mm in the majority of cases biopsied, and that these sub-centimetre short axis lymph nodes did not have any specific sonographic appearances to mark them as pathological. Nevertheless histological examination revealed non-caseating granulomas in all cases. In a further two cases, where no neck nodes were seen, a histological diagnosis of sarcoidosis was made from biopsy of diffusely abnormal parotid gland tissue.
Conclusions Given the clear advantages of cervical diagnosis in terms of invasiveness and economy compared to mediastinal alternatives, it is suggested that where the expertise for core biopsy of normal sized cervical lymph nodes is readily available, the technique may be considered as a first line investigation for the diagnosis of sarcoidosis. Background Bronchoalveolar lavage (BAL) is a widely used diagnostic tool for suspected Interstitial Lung Disease (ILD) patients and is advocated in ILD guidelines. 1 We aimed to evaluate the quality of BAL sampling in the diagnosis of ILD compared to BAL guidelines. Results 416 patients' coded as BAL sampling. 95 (24%) were performed in the diagnostic strategy for ILD. The mean age was 58.9 (range 18-89). 36 (37.9%) were Female and 59 (62.1%) were male.13 (13.7%) had lymphocyte count 15%,
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